13F Holdings
中文EN

ANIX Anixa Biosciences Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 715446 · Fiscal year ends 10/31

Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.6%
TTM EPS YoY5.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-66.8%
ROA-63.4%
ROIC (approx.)-61.6%
Asset turnover—

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.54x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.71x
Accruals ratio-18.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-10-31FY20242024-10-31FY20232023-10-31FY20222022-10-31FY20222021-10-31
Income statement
Revenue—$210,000$210,000—$512,000
R&D expense$5.07M$6.40M$4.77M$6.70M$6.19M
SG&A expense$6.63M$7.43M$6.29M$7.17M$7.07M
Operating income-$11.70M-$13.83M-$11.01M-$13.88M-$13.14M
Net income-$10.93M-$12.55M-$9.81M-$13.60M-$12.95M
EPS (basic)-0.34-0.39-0.320.45-0.45
EPS (diluted)-0.34-0.39-0.320.45-0.45
Weighted avg. shares (diluted)32,45431,89830,98030,37428.58M
Balance sheet
Cash & equivalents$1.24M$1.27M$915,000$12.36M$29.13M
Short-term investments$13.93M$18.65M$22.93M$17.33M$6.60M
Receivables—$173,000$270,000$46,000—
Current assets$15.89M$21.36M$25.36M$30.20M$36.00M
Total assets$16.08M$21.59M$25.52M$30.41M$36.26M
Current liabilities$1.97M$2.50M$2.03M$2.04M$1.27M
Total liabilities$2.13M$2.70M$2.15M$2.21M$1.49M
Shareholders' equity$15.16M$20.00M$24.34M$29.05M$35.44M
Shares outstanding33.01M32.20M31.15M30.91M30.05M
Cash flow statement
Operating cash flow-$7.17M-$7.33M-$6.21M-$6.49M-$4.94M
Investing cash flow$4.87M$4.28M-$5.60M-$10.73M-$3.92M
Financing cash flow$2.28M$3.42M$366,000$452,000$31.57M
Stock-based compensation$3.68M$4.42M$4.42M$6.00M$7.50M
Share buybacks—$6,000———

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.